Multi-centre observational study of buprenorphine use in 32 Italian drug addiction centres.
OBJECTIVE
To examine how buprenorphine is currently being used across Italy, and to identify simultaneously best practice protocols to guide physicians in optimising the safety and efficacy of this treatment option.


METHODS
Retrospective, observational, multi-centre study.


METHODS
A total of 979 opioid-dependent patients were included from 32 centres involving the initiation of 1122 treatments.


RESULTS
During the study period 33.4% of patients relapsed during the induction phase. Lower induction doses resulted in markedly higher relapse rates (51.2% of those who received 2 mg versus 20.6% of those who received 10mg of buprenorphine relapsed). Over 89% of patients who received 16 mg of buprenorphine during the induction phase successfully went on to maintenance treatment. The percentage of drug-positive urines also decreased over time on buprenorphine treatment (cocaine-positive urines decreased from 25.8% at study entrance to 0% at 24 months). Psychosocial support in addition to buprenorphine pharmacotherapy further decreased the risk of relapse and was associated with lower levels of heroin craving. Retention in treatment was increased by less-than-daily dosing of buprenorphine.


CONCLUSIONS
Higher induction doses of buprenorphine significantly decreased relapse rates and increased the percentage of patients achieving maintenance treatment. Psychosocial support and/or less-than-daily dosing also appeared to promote positive treatment outcomes.
Leonardi
C
C
District Unit for the Prevention and Treatment of Drug Dependence and Alcoholism, Drug Addiction Centre D/XI-ASL Rome C, Via Appia Antica, 220, 00178 Rome, Italy. leonardiclaudio@jumpy.it
Hanna
N
N
Laurenzi
P
P
Fagetti
R
R
D000328:Adult; D002047:Buprenorphine / Q000008:administration & dosage / Q000627:therapeutic use*; D003042:Cocaine / Q000652:urine; D003710:Demography; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D009294:Narcotics / Q000008:administration & dosage / Q000627:therapeutic use*; D019370:Observation; D009293:Opioid-Related Disorders / Q000453:epidemiology* / Q000534:rehabilitation*; D011584:Psychology; D012189:Retrospective Studies; D016320:Substance Abuse Treatment Centers / Q000706:statistics & numerical data*
D009294:Narcotics; D002047:Buprenorphine; D003042:Cocaine